Pennsylvania: Medical Marijuana: Turning Over on Leaf

Authored By: William F. McDevitt, Esq.

In early April, Pennsylvania’s Medical Marijuana Advisory Board (Board) delivered a report to the Department of Health (DOH) recommending changes to the medical marijuana program. Among the proposed reforms – recognizing additional medical conditions as cannabis-treatable (neurodegenerative diseases, dyskinetic and spastic movement disorders, opioid addiction treatment and terminal illness), allowing physicians to opt out of DOH’s public registry, and allowing licensed dispensaries to sell cannabis in dry leaf and flower form.

The Board’s recommendation to allow leaf and flower cannabis is both ambitious and predictable. In 2016, Governor Tom Wolf signed the Medical Marijuana Act (MMA). That same year, parallel proposed legislation seeking to legalize adult-use or “recreational” marijuana failed. The Pennsylvania Legislature attempted to avoid stigmatizing the medical marijuana program by focusing on medical treatment and statutorily prohibiting practices associated with “pot.” The MMA requires physician participation, patient and physician registration, medical research and statistical studies. The sale of dry leaf, flower or edible cannabis is prohibited, as is the smoking of cannabis in any form. Pills, tinctures, oils, topicals and vaporizable liquids are the only permissible forms of medical cannabis and only when bearing DOH-approved labeling.

The “pot” stigma continues on a local level. Many licensed grower/processors and dispensaries have faced opposition from local zoning boards, forcing several to relocate. Dispensaries may face renewed opposition from municipalities if they are permitted to sell cannabis in leaf and flower form. It is also anticipated that local police departments will oppose the sale of medical leaf and flower cannabis, which would be visually indistinguishable from illegal cannabis.

But change may be unavoidable. Of the 29 states that have enacted medical marijuana laws, only Minnesota and Pennsylvania prohibit the sale of dry leaf or flower cannabis (though New York, Ohio and West Virginia presently prohibit the smoking of medical cannabis). Since February 2018, licensed dispensaries have delivered cannabis, cultivated and processed in the Commonwealth, to certified patients in Pennsylvania. Patients have complained about high prices for processed cannabis, which is not covered by insurance. Although more grower-processor, dispensary and clinical registrant licenses are expected to be awarded by the end of this year, dispensaries have reported problems maintaining stock in the face of patient demand.

Leaf and flower cannabis is cheaper to produce than the processed forms presently allowed under the MMA. The lack of processing allows the product to move faster from cultivator to patient. Research has not yet ruled out the possibility that processing may remove compounds that could be beneficial in treating certain medical conditions.

The DOH has one year to consider the Board’s report before making its own recommendations. Ultimately, the Pennsylvania Legislature will need to decide whether the MMA should be amended to remove the statutory prohibition on leaf and flower cannabis. Only time will tell whether patient access to medical treatment will overcome the stigma associated with leaf and flower marijuana.

About the Author

William F. McDevitt is a partner in the Philadelphia office of national law firm Wilson Elser, where he is a member of the firm’

Top 200 Cannabis Lawyers

We Support

Cannabis Law Journal – Contributing Authors

Editor – Sean Hocking

Author Bios

Canada
Matt Maurer – Minden Gross
Jeff Hergot – Wildboer Dellelce LLP

Costa Rica
Tim Morales – The Cannabis Industry Association Costa Rica

Nicaragua
Elvin Rodríguez Fabilena

USA

General
Julie Godard
Carl L Rowley -Thompson Coburn LLP

Arizona
Jerry Chesler – Chesler Consulting

California
Ian Stewart – Wilson Elser Moskowitz Edelman & Dicker LLP
Otis Felder – Wilson Elser Moskowitz Edelman & Dicker LLP
Lance Rogers – Greenspoon Marder – San Diego
Jessica McElfresh -McElfresh Law – San Diego
Tracy Gallegos – Partner – Fox Rothschild

Colorado
Adam Detsky – Knight Nicastro
Dave Rodman – Dave Rodman Law Group
Peter Fendel – CMR Real Estate Network
Nate Reed – CMR Real Estate Network

Florida
Matthew Ginder – Greenspoon Marder
David C. Kotler – Cohen Kotler

Illinois
William Bogot – Fox Rothschild

Massachusetts
Valerio Romano, Attorney – VGR Law Firm, PC

Nevada
Neal Gidvani – Snr Assoc: Greenspoon Marder
Phillip Silvestri – Snr Assoc: Greenspoon Marder

Tracy Gallegos – Associate Fox Rothschild

New Jersey

Matthew G. Miller – MG Miller Intellectual Property Law LLC
Daniel T. McKillop – Scarinci Hollenbeck, LLC

New York
Gregory J. Ryan, Esq. Tesser, Ryan & Rochman, LLP
Tim Nolen Tesser, Ryan & Rochman, LLP
Cadwalader, Wickersham & Taft LLP

Oregon
Paul Loney & Kristie Cromwell – Loney Law Group
William Stewart – Half Baked Labs

Pennsylvania
Andrew B. Sacks – Managing Partner Sacks Weston Diamond
William Roark – Principal Hamburg, Rubin, Mullin, Maxwell & Lupin
Joshua Horn – Partner Fox Rothschild

Washington DC
Teddy Eynon – Partner Fox Rothschild